The Uncomfortable Truth About Offshore Medical Case Review

Some firms outsource initial medical malpractice case screening to “offshore” (i.e., non-U.S. clinical experience) physicians (and even medical students) to cut costs.

Trust me, I understand the impulse. Expert review is expensive and slow, and the volume of records that need to move through intake before a single viable case emerges can be staggering. Anything that reduces the bottleneck — and the overhead — seems worth trying. The math looks reasonable on a spreadsheet.

But the math changes when you look at what you're actually getting. As the expression goes, “four 3rd graders, don’t make a 12th grader.” And when you’re betting your money, energy, and reputation on reliable case merit assessment, quality beats quantity every day.  

An international reviewer would be hard pressed to have a deep understanding of American standards of care, which necessarily vary by state, by facility type, and by the specific clinical context. Emergency medicine practiced in a rural critical access hospital is not the same as emergency medicine practiced at a Level I trauma center. Obstetric care in Texas operates under different medicolegal assumptions than obstetric care in California. And rural California is different from L.A. and so forth . These distinctions are not incidental — they may seem trivial, but they are often the entire case.

A reviewer without malpractice litigation experience who doesn't understand what "strength of evidence" means from a legal standpoint can be a hidden liability. Clinical medicine and legal analysis of care are related, but they are not the same discipline. A physician who has never been deposed, never reviewed a case for litigation, and never had their opinion tested under cross-examination is missing a layer of judgment that only comes from that exposure. They may identify something that looks wrong clinically without understanding whether it's actionable — or defensible.

A student who knows nothing of clinical practice realities can’t reliably differentiate a complication from a deviation. Those are very different things clinically, and confusing them kills cases — or worse, advances cases that would have been better to have passed on. 

And then there's the discovery problem — one that doesn't get discussed enough.

If it ever comes up in discovery: "Who initially screened this case for your firm, and what were their qualifications?" — you want a defensible answer. Not because you're legally required to disclose the full chain of review in every jurisdiction, but because how a firm answers that question says something about how seriously they take their intake process. Opposing counsel will notice. In a trial setting, judges will notice. And in a case that's already too close for comfort, the credibility of your pre-litigation process can matter.

The screening phase isn't where you cut corners. It's the foundation of every case you build and every case you decline and it’s what, in large measure, separates the outstanding attorneys from the competition. 

Warren Buffet famously said “For every hundred great opportunities that are bought to me, I say NO ninety-nine times.”  This encapsulates the value of a high-quality screen at the precise moment of deciding to invest anything into the case or to pass and move on. 

Furthermore, a bad screen doesn't just let a weak case through — it shapes the theory of the case, the experts you retain, the damages narrative you build. You're not just reviewing records at intake. You're making a series of downstream decisions that become very expensive to reverse.

The cost of a bad screen is always more than the cost of a good one. In the same way that taking a wrong turn at the beginning of a journey is disproportionately consequential, bad intel during case screening can lead to an ineffective and misguided allotment of precious and finite resources.  That's not a platitude — it's arithmetic.